News UroGen Pharma Ltd.

Equities

URGN

IL0011407140

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
13.22 ^USD	+0.08%		+3.77%	-11.87%

May. 14	Oppenheimer Lowers UroGen Pharma Price Target to $32 From $34, Maintains Outperform Rating	MT
May. 13	Transcript : UroGen Pharma Ltd., Q1 2024 Earnings Call, May 13, 2024

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oppenheimer Lowers UroGen Pharma Price Target to $32 From $34, Maintains Outperform Rating	May. 14	MT
Transcript : UroGen Pharma Ltd., Q1 2024 Earnings Call, May 13, 2024	May. 13
Earnings Flash (URGN) UROGEN PHARMA Posts Q1 Revenue $18.8M, vs. Street Est of $21.4M	May. 13	MT
UroGen Pharma Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights	May. 13	BU
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates	May. 07	MT
UroGen Pharma to Participate at Upcoming Investor Conferences	May. 07	BU
UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024	May. 06	AQ
UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024	May. 06	AQ
UroGen Pharma Ltd. - New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival at 24 Months with JELMYTO across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy	May. 06	AQ
UroGen Pharma Ltd. - New Real-World Study on Retrograde Instillation of JELMYTO for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial	May. 06	AQ
UroGen Pharma Ltd. Reports on New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy	May. 05	CI
New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy	May. 05	BU
UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024	May. 04	BU
New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial	May. 04	BU
UroGen Pharma Ltd. Reports New Real-World Study on Retrograde Instillation of JELMYTO for Treatment of Low-Grade Upper Tract Urothelial Cancer	May. 04	CI
UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024	May. 03	BU
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers	Apr. 17	BU
NORTHSTAR APPOINTS PETER PFREUNDSCHUH TO BOARD OF MANAGERS	Apr. 16	AQ
UroGen Pharma Says FDA Accepts Investigational New Drug Application for Potential Bladder Cancer Treatment	Apr. 15	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News UroGen Pharma Ltd.

Equities

URGN

IL0011407140

Summary

Filters